What is LGNYZ's health score?

LIGAND PHARMACEUTICALS INC (LGNYZ) has a TradeApes health score of 57 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is LGNYZ's estimated fair value?

Based on our 5-year discounted cash flow model, LIGAND PHARMACEUTICALS INC's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is LGNYZ undervalued or overvalued?

Our model currently rates LGNYZ as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for LGNYZ... Refresh in a moment for the full analysis.

LIGAND PHARMACEUTICALS INC (LGNYZ)

Healthcare Fair Value High mixed

Updated: 2026-04-21

TradeApes Score

hold

Financial Strength

80 Strong

Operating Trend

55 Mixed

Relative Value

60 Healthy

Capital Allocation

10 Stressed

Risk

70 Healthy

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.